Chronic infectious disease and the future of health care delivery

New England Journal of Medicine

Volumn 369, Issue 25, 2013, Pages 2424-2436

  Farmer, Paul E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; BOCEPREVIR; DARUNAVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; COMMUNITY CARE; CONFERENCE PAPER; DRUG COST; DRUG RESISTANT TUBERCULOSIS; EPIDEMIC; HEALTH CARE DELIVERY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; MIXED INFECTION; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; CHRONIC DISEASE; FORECASTING; HISTORY; HIV INFECTIONS; TRENDS; TUBERCULOSIS, PULMONARY; ARTICLE; LUNG TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; CHRONIC DISEASE; DELIVERY OF HEALTH CARE; FORECASTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; INFECTION; TUBERCULOSIS, PULMONARY;

EID: 84890335224     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa1310472     Document Type: Conference Paper

References (87)

1. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
2. Kim JY, Farmer PE, Porter ME. Redefining global health-care delivery. Lancet 2013;382:1060-9.
3. Herbert B. In America, refusing to save Africans. New York Times, June 11, 2001 (http://www.nytimes.com/2001/06/11/opinion/in-america-refusing-to-save- africans.html).
4. Farmer PE. The major infectious diseases in the world - to treat or not to treat? N Engl J Med 2001;345:208-10.
5. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012;367:931-6.
6. Mitnick CD, Bayona J, Palacios E, et al. Community-based therapy for multi-drug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28.
7. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006;10:402-8.
8. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009;4(9):e7186.
9. Mukherjee JS, Shin S, Furin J, et al. New challenges in the clinical management of drug-resistant tuberculosis. Infect Dis Clin Pract 2002;11:329-39.
10. Binagwaho A. Resistant TB: use the tools available. Nature 2013;494:176.
11. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010;14:1233-43.
12. Primary multidrug-resistant tuberculosis - Ivanovo Oblast, Russia, 1999. MMWR Morb Mortal Wkly Rep 1999;48:661-4.
13. Farmer PE. Managerial successes, clinical failures. Int J Tuberc Lung Dis 1999;3:365-7.
14. Farmer PE, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Semin Respir Infect 1991;6:254-60.
15. Walker J, Tadena N. J&J tuberculosis drug gets fast-track clearance. Wall Street Journal. December 31, 2012 (http://online.wsj.com/news/articles/ SB10001424127887323320404578213421059138236).
16. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011;154:766-71.
17. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
18. Leland J. The end of AIDS? Newsweek, December 2, 1996:64-73.
19. Members of the Faculty of Harvard University. Consensus Statement on antiretroviral treatment for AIDS in poor countries. Cambridge, MA: Harvard University Center for International Development. March 4, 2001 (http://www.cid.harvard.edu/cidinthenews/pr/consensus-aids-therapy.pdf).
20. Farmer PE. Prevention without treatment is not sustainable. National AIDS Bulletin (Australia) 2000;13:6-9.
21. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002;359:1851-6.
22. Smith R, Siplon P. Drugs into bodies: global AIDS treatment activism. Westport, CT: Praeger, 2006.
23. Pape JW, Liautaud B, Thomas F, et al. Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti. N Engl J Med 1983;309:945-50.
24. Farmer PE. Letter from Haiti. AIDS Clin Care 1997;9:83-5.
25. Global tuberculosis report 2013. Geneva: World Health Organization, 2013.
26. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-72.
27. Desormeaux J, Johnson MP, Coberly JS, et al. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population. Bull Pan Am Health Organ 1996;30:1-8.
28. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001;15:143-52.
29. Farmer PE, Léandre F, Koenig S, et al. Preliminary outcomes of directly-observed treatment of advanced HIV disease with ARVs (DOT-HAART) in rural Haiti. Presented at the 10th Annual Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003. abstract.
30. Farmer PE, Léandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001;358:404-9.
31. Farmer PE, Léandre F, Mukherjee JS, Gupta R, Tarter L, Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001;79:1145-51.
32. Antenatal HIV and syphilis prevalence survey. Cape Town, South Africa: Department of Health, 2001.
33. Tuberculosis service review, Khayelitsha health district. Cape Town, South Africa: Department of Health, 2002.
34. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.
35. Kim JY, Ammann A. Is the "3 by 5" initiative the best approach to tackling the HIV pandemic? PLoS Med 2004;1(2):e37.
36. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-34.
37. Koenig SP, Léandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004;18:Suppl 3:S21-S25.
38. Garrett L. Bragging in Bangkok. New York Times. July 16, 2004.
39. Walton DA, Farmer PE, Lambert W, Léandre F, Koenig SP, Mukherjee JS. Integrated HIV prevention and care strengthens primary health care: lessons from rural Haiti. J Public Health Policy 2004;25:137-58.
40. Jerome G, Ivers LC. Community health workers in health systems strengthening: a qualitative evaluation from rural Haiti. AIDS 2010;24:Suppl 1:S67-S72.
41. Dowell SF, Tappero JW, Frieden TR. Public health in Haiti - challenges and progress. N Engl J Med 2011;364:300-1.
42. UNAIDS. AIDSInfo database (http://www.unaids.org/en/dataanalysis/ datatools/aidsinfo).
43. Monitoring, Evaluation, and Surveillance Interface (MESI). Patients actifs sous ARV entre Mai 2013 et Août 2013 (http://mesi.ht/ PresentationLayer/RapportsAnalyses/wbfrm-RapportAnalyseTableaux2.aspx?activeTab= tab-rapports-analyses&ID=35).
44. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization, 2013.
45. Rouzier V, Farmer P, Pape JW, et al. Factors impacting the provision of antiretroviral therapy to people living with HIV: the view from Haiti. Antivir Ther (in press).
46. Pape J, Johnson WD Jr. AIDS in Haiti: 1982-1992. Clin Infect Dis 1993;17:Suppl 2:S341-S345.
47. Enquête mortalité, morbidité et utilisation des services, Haiti 2012: rapport préliminaire. Pétion-Ville, Haiti: Institut Haïtien de l'Enfance, 2012.
48. Rich ML, Miller AC, Niyigena P, et al. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr 2012;59(3):e35-e42.
49. Towards universal access - scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization, 2010 (http://whqlibdoc.who.int/publications/2010/9789241500395-eng.pdf).
50. DataBank: world development indicators and global development finance. Washington, DC: World Bank, 2013 (http://databank.worldbank.org).
51. Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One 2013;8(1):e53586.
52. Binagwaho A, Ngabo F, Wagner CM, et al. Integration of comprehensive women's health programmes into health systems: cervical cancer prevention, care and control in Rwanda. Bull World Health Organ 2013;91:697-703.
53. United Nations General Assembly. Political declaration of the high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases. Sixty-sixth session, agenda item 117, Doc. A/66/L.1. September 16, 2011 (http://www.un.org/ga/search/view-doc.asp?symbol=A/66/L.1).
54. Amoroso CL, Akimana B, Wise B, Fraser HS. Using electronic medical records for HIV care in rural Rwanda. Stud Health Technol Inform 2010;160:337-41.
55. Lu C, Chin B, Lewandowski JL, et al. Towards universal health coverage: an evaluation of Rwanda Mutuelles in its first eight years. PLoS One 2012;7(6):e39282.
56. Farmer PE, Nutt CT, Wagner CM, et al. Reduced premature mortality in Rwanda: lessons from success. BMJ 2013;346:f65.
57. UN Inter-agency Group for Child Mortality Estimation. Levels and trends in child mortality. New York: United Nations Children's Fund, 2012 (www.unicef.org/media/files/UNICEF-2012-IGME-child-mortality-report.pdf).
58. Gapminder Foundation. Data in Gapminder World (http://www.gapminder.org/ data).
59. Special report: how Africa turned AIDS around. Geneva: UNAIDS, 2013 (http://www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2013/20130521-Update-Africa.pdf).
60. Fauci AS, Folkers GK. The world must build on three decades of scientific advances to enable a new generation to live free of HIV/AIDS. Health Aff (Millwood) 2012;31:1529-36.
61. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
62. Holmes CB, Coggin W, Jamieson D, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 2010;304:313-20.
63. Soni A, Gupta R. Bridging the resource gap: improving value for money in HIV/AIDS treatment. Health Aff (Millwood) 2009;28:1617-28.
64. World AIDS Day Report. Geneva: UNAIDS, 2012 (http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2012/gr2012/ jc2434-worldaidsday-results-en.pdf).
65. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-90.
66. Park P, Bhatt A, Rhatigan J. The academic model for the prevention and treatment of HIV/AIDS: cases in global health delivery. Boston: GHD Online, April 2011.
67. Inui TS, Nyandiko WM, Kimaiyo SN, et al. AMPATH: living proof that no one has to die from HIV. J Gen Intern Med 2007;22:1745-50.
68. Ocfemia CB, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. Presented at the 19th Annual Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012. abstract.
69. Andrews JR, Lawn SD, Dowdy DW, Walensky RP. Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. Clin Infect Dis 2013;57:1021-6.
70. Keshavjee S, Farmer PE. Picking up the pace - scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010;363:1781-4.
71. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81.
72. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009;48:829-31.
73. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
74. Philpott S, Schüklenk U. Bioethics forum: a study that should not have been done. Garrison, NY: Hastings Center, May 5, 2010 (http://www. thehastingscenter.org/Bioethicsforum/Post.aspx?id=4626).
75. Farmer P, Murray M, Hedt-Gauthier B. Clinical trials and global health equity. Lancet Global Health blog. July 8, 2013 (http://globalhealth.thelancet. com/2013/07/08/clinical-trials-and-global-health-equity).
76. Franke MF, Robins JM, Mugabo J, et al. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med 2011;8(5):e1001029.
77. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
78. Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M. Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol 2011;49:385-8.
79. Pedersen D, Larson E. Too poor to treat. Newsweek. July 28, 1997:60.
80. Emery N. Rwanda's historic health recovery: what the US might learn. The Atlantic. February 20, 2013 (http://www.theatlantic.com/health/archive/2013/02/ rwandas-historic-health-recovery-what-the-us-might-learn/273226).
81. Binagwaho A, Nutt CT, Mutabazi V, et al. Shared learning in an interconnected world: innovations to advance global health equity. Global Health 2013;9:37.
82. Schroeder SA. Shattuck Lecture: we can do better - improving the health of the American people. N Engl J Med 2007;357:1221-8.
83. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38:Suppl 5:S429-S436.
84. Hill A, Khoo S, Simmons B, Ford N. Minimum costs to produce hepatitis C direct acting antivirals. Presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington DC, November 7-11, 2013 (oral presentation).
85. Gupta R, Kim JY, Espinal MA, et al. Public health: responding to market failures in tuberculosis control. Science 2001;293:1049-51.
86. Silverman E. Will the new hepatitis C drugs trigger a battle over cost? Forbes. November 11, 2013 (http://www.forbes.com/sites/edsilverman/2013/11/11/ will-the-new-hepatitis-c-drugs-trigger-a-battle-over-cost).
87. Untangling the web of antiretroviral price reductions: 16th ed. Geneva: Médecins Sans Frontières, July 2013 (http://d2pd3b5abq75bb. cloudfront.net/2013/09/11/10/25/44/896/MSF-Access-UTW-16th-Edition-2013.pdf).